Protocol 849-017: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
KRAS G12C inhibitor adagrasib in combination with pemetrexed and pembrolizumab.
Unresectable or metastatic KRAS G12C mutant non-squamous non-small cell lung cancer treated with 4 cycles of platinum-based chemotherapy and pembrolizumab as first line treatment.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology
Contact us today to request an appointment.Virtual & Telemedicine available.